Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : Just – Evotec Biologics announces product development and manufacturing agreement with OncoResponse

share with twitter share with LinkedIn share with facebook
share via e-mail
01/16/2020 | 04:43am EST
Just - Evotec Biologics announces product development and manufacturing agreement with OncoResponse
  • JUST - EVOTEC BIOLOGICS WILL APPLY ITS FULLY INTEGRATED TECHNOLOGY PLATFORM IN ORDER TO ACCELERATE ONCORESPONSE'S LEAD PRODUCT CANDIDATE THROUGH DEVELOPMENT AND INTO THE CLINIC

Hamburg, Germany, 16 January 2020:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its wholly-owned Seattle-based subsidiary company Just - Evotec Biologics, Inc. has established a collaborative relationship with OncoResponse, Inc., a biotech company developing human antibodies as product candidates for multiple high value targets associated with immunosuppressive myeloid biology. OncoResponse's lead antibody product candidate, OR2805, is a fully human antibody derived from an elite responder that reverses immunosuppression in the tumour microenvironment and promotes greater cancer killing that will lead to higher response rates and more cures.

Under the agreement, Just - Evotec Biologics will leverage its integrated technology platform, J.DESIGN, to provide OncoResponse with services to accelerate OR2805 into the clinic. The services include cell line development, process development, and Phase I/II cGMP clinical manufacturing of a selected drug candidate for use in human clinical trials.

Clifford Stocks, Chief Executive Officer of OncoResponse, commented: 'We are thrilled to have Just - Evotec Biologics develop and manufacture our lead therapeutic antibody. Just - Evotec Biologics' background, expertise and guidance combined with their track record and unique technology platform will play a critical role in the successful production of our molecule for clinical studies.'

Dr James Thomas, EVP Global Head Biotherapeutics, President U.S. Operations at Just - Evotec Biologics, commented: 'We are delighted to be working with the experienced and dynamic team at OncoResponse on the development and manufacturing of this exciting immunotherapy approach to cancer.'

ABOUT ONCORESPONSE

OncoResponse, Inc., an immuno-oncology focused biotech company, in a broad strategic alliance with MD Anderson Cancer Center uses a proprietary B-cell technology platform to mine the immune system of cancer patients who have responded to cancer immunotherapy to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies to treat cancer. OncoResponse has several antibodies directed at modulating immunosuppression of the tumor microenvironment in pre-clinical development. OncoResponse, Inc. is a privately held company backed by investment from MD Anderson Cancer Center, Rivervest Venture Partners, Qatar Investment Authority, Redmile Group, ARCH Venture Partners, GreatPoint Ventures, Helsinn Investment Fund, Canaan Partners, Shire, Buchang Pharma (China), Alexandria Real Estate Equities and William Marsh Rice University. For more information please visit: www.oncoresponseinc.com

ABOUT JUST - EVOTEC BIOLOGICS

Just - Evotec Biologics wholly owned by Evotec SE is a unique platform company that integrates the design, engineering, development, and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus is to create access and value for a global market through scientific and technological innovation. Learn more at www.just.bio.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

TOP

Disclaimer

Evotec SE published this content on 16 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 January 2020 09:42:00 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EVOTEC SE
02/13EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
02/11EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
02/07EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
02/05EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
02/03EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
01/31EVOTEC : and Bayer advance further programme into Phase I clinical development
AQ
01/31EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
01/30EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
01/30EVOTEC : And bayer advance further programme into phase i clinical development
EQ
01/29EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
More news
Financials (EUR)
Sales 2019 429 M
EBIT 2019 59,5 M
Net income 2019 36,1 M
Finance 2019 5,50 M
Yield 2019 -
P/E ratio 2019 107x
P/E ratio 2020 81,1x
EV / Sales2019 9,02x
EV / Sales2020 7,96x
Capitalization 3 877 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 29,63  €
Last Close Price 25,69  €
Spread / Highest target 28,5%
Spread / Average Target 15,3%
Spread / Lowest Target -2,69%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE13.88%4 276
LONZA GROUP18.83%31 906
IQVIA HOLDINGS INC.6.39%31 697
SEATTLE GENETICS, INC.4.93%20 652
CELLTRION, INC.--.--%19 382
INCYTE CORPORATION-9.18%17 867